Since our study excluded patients at risk for increased FN frequency, such as those with hematopoietic dysfunction, advanced cancer, or serious complications (renal or hepatic dysfunction), we attribute this difference to the higher frequency of ANC measurements in our study. The gene discussed is FN1; the disease is cancer.